Baird Reiterates Buy Rating for Larimar Therapeutics
Baird maintains its 'buy' rating on Larimar Therapeutics, targeting $5 per share, a 63.93% upside from the current price.
Key Points
- Baird reiterated its 'buy' rating for Larimar Therapeutics, Inc. (LRMR) with a price target of $5 as of June 30, 2026.
- Baird's $5 price target implies 63.93% upside from Larimar Therapeutics, Inc.'s ($LRMR) current $3.05 share price.
- Shares of Larimar Therapeutics traded around $3.20 on Wednesday, with a market cap of approximately $316.8 million.
- Larimar Therapeutics saw insider buying in May 2026, while Deerfield Management increased its stake by 5 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Baird reiterated its 'buy' rating for Larimar Therapeutics, Inc. (NasdaqGM: LRMR), setting a price target of $5. Analyst Joel Beatty's reaffirmation comes as the stock traded around $3.20 on Wednesday.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Larimar Therapeutics
Deerfield Management Company, L.P. increased its stake in Larimar Therapeutics by 5 million shares, bringing its total to 35,606,974 shares valued at about $160.2 million. Blue Owl Capital Holdings LP added 296,317 shares, now holding 7,120,007 shares worth approximately $32.0 million. BlackRock, Inc. also upped its position by 70,597 shares, totaling 3,752,200 shares valued at $16.9 million. Conversely, Millennium Management LLC reduced its holdings by 1,581,086 shares, ending with 3,625,278 shares worth $16.3 million. AIGH Capital Management LLC significantly increased its stake by 1 million shares, now holding 3 million shares valued at $13.5 million.
Larimar Therapeutics, Inc. Stock Down 23.9%
Shares of Larimar Therapeutics, Inc. traded near $3.20 on Wednesday. The company, with a market cap of about $316.8 million, operates in the biotechnology industry with a focus on rare disease treatments. It has a beta of 0.817, indicating lower volatility compared to the market. The stock's 52-week range is between $2.72 and $6.42. Its current ratio is 4.292, and it has a debt-to-equity ratio of 2.391.
$LRMR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Larimar Therapeutics, Inc.
In May 2026, several insiders, including Joseph Truitt and Jonathan Leff, each purchased 55,150 shares of Larimar Therapeutics. These transactions were not part of any planned trading scheme and indicate a potential vote of confidence from the insiders.
Analysts Set New Price Targets
On June 30, 2026, Baird maintained its 'buy' rating on Larimar Therapeutics with a $5 price target. Previously, on May 27, 2026, JP Morgan initiated coverage with a 'buy' rating and a $9 target. Wedbush has consistently maintained a 'buy' rating, with targets ranging from $11 to $13 in 2026. The consensus among analysts is a 'strong buy' with an average target price of $15.11 across nine opinions.
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania. It focuses on developing treatments for rare diseases using its unique cell-penetrating peptide technology. The company's lead product candidate, CTI-1601, is currently in Phase 2 OLE clinical trials for treating Friedreich's ataxia, a rare and progressive disease. Dr. Carole S. Ben-Maimon leads the company as CEO, and it employs approximately 71 people.
Bottom Line
Baird's reiteration of its 'buy' rating for Larimar Therapeutics highlights ongoing confidence in the company's potential, especially with its focus on rare diseases. Investors often track such analyst ratings as they provide insights into market expectations. It's important to remember that these ratings and targets reflect analysts' views and are subject to change.
Get Larimar Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LRMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.